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Abstract
Introduction: The main prognostic variables in early breast cancer are tumor size, histological grade, estrogen
receptor/progesterone receptor (ER/PgR) status, number of positive nodes and human epidermal growth factor
receptor 2 (HER2) status. The present study evaluated the prognostic and/or predictive value of vascular endothelial
growth factor (VEGF) family members in high-risk early breast cancer patients treated with adjuvant chemo-
hormonotherapy.
Methods: RNA was isolated from 308 formalin-fixed paraffin-embedded primary tumor samples from breast cancer
patients enrolled in the HE10/97 trial, evaluating adjuvant dose-dense sequential chemotherapy with epirubicin
followed by cyclophosphamide, methotrexate, fluorouracil (CMF) with or without paclitaxel (E-T-CMF versus E-CMF).
A fully automated method based on magnetic beads was applied for RNA extraction, followed by one-step quantitative
RT-PCR for mRNA analysis of VEGF-A, -B, -C and vascular endothelial growth factor receptor (VEGFR) 1, 2, 3.
Results: With a median follow-up of 8 years, 109 patients (35%) developed a relapse and 80 patients (26%) died. In
high VEGF-C and VEGFR1 mRNA expressing tumors, ER/PgR-negative tumors (Fisher’s exact test, P = 0.001 and
P = 0.021, respectively) and HER2-positive tumors (P <0.001 and P = 0.028, respectively) were more frequent than in low
VEGF-C and VEGFR1 expressing tumors, respectively. From the VEGF family members evaluated, high VEGFR1 mRNA
expression (above the 75th percentile) emerged as a significant negative prognostic factor for overall survival
(OS; hazard ratio (HR) = 1.60, 95% confidence interval (CI): 1.01 to 2.55, Wald’s P = 0.047) and disease-free survival (DFS;
HR = 1.67, 95% CI: 1.13 to 2.48, P = 0.010), when adjusting for treatment group. High VEGF-C mRNA expression was
predictive for benefit from adjuvant treatment with paclitaxel (E-T-CMF arm) for OS (test for interaction, Wald’s P =
0.038), while in multivariate analysis the interaction of VEGF-C with taxane treatment was significant for both OS (Wald’s
P = 0.019) and DFS (P = 0.041) and continuous VEGF-B mRNA expression values for OS (P = 0.019).
Conclusions: The present study reports, for the first time, that VEGF-C mRNA overexpression, as assessed by qRT-PCR,
has a strong predictive value in high-risk early breast cancer patients undergoing adjuvant paclitaxel-containing
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treatment. Further studies are warranted to validate the prognostic and/or predictive value of VEGF-B, VEGF-C and
VEGFR1 in patients treated with adjuvant therapies and to reveal which members of the VEGF family could possibly be
useful markers in identifying patients who will benefit most from anti-VEGF strategies.
Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12611000506998
Introduction
The main prognostic variables in early breast cancer are
tumor size, grade, estrogen and progesterone receptor
(ER/PgR) status, number of positive nodes and human epi-
dermal growth factor receptor 2 (HER2) status [1]. These
and other clinicopathological parameters are commonly
utilized to identify patients who are more likely to benefit
from adjuvant chemotherapy and hormonal therapy. How-
ever, a large number of other molecules are being exten-
sively investigated for their predictive and prognostic
value, since most existing clinicopathological models have
only moderate predictive power and do not account for
the molecular diversity of tumors [2].
Recent experimental and clinical studies have suggested
the essential role of angiogenesis in breast cancer among
many other tumor types. The members of the vascular
endothelial growth factor (VEGF) family and their recep-
tors (VEGFRs) have a central function in angiogenesis
and the formation of vascular networks. Today, we recog-
nize five VEGFs (VEGF-A, -B, -C, -D, -E), with the first
three being better characterized. VEGF-A and -B are
considered mainly angiogenic, while VEGF-C is thought
to be more lymphangiogenic. Their binding partners are
three different tyrosine kinase receptors, VEGFR1 (or
Flt-1), VEGFR2 (or KDR/Flk-1) and VEGFR3 (or Flt-4)
[3,4]. VEGF-A is expressed at low levels in normal adult
life and is over-expressed during wound healing and tis-
sue regeneration. It has two known receptors, VEGFR1
and 2, mainly expressed in endothelial cells. VEGF-B is
expressed at higher levels in cardiac and skeletal muscle
cells, it forms heterodimers with VEGF-A and has two
known binding receptors, VEGFR1 and neuropilin-1.
VEGF-C was initially identified as a ligand for the tyro-
sine kinase receptor VEGFR3, which is associated with
the lymphatic vasculature [5]. VEGF-C is also a ligand for
VEGFR2, which it shares with VEGF-A and -D. A num-
ber of recent studies have investigated the role of VEGF-
C in human tumors [6]; however, few have explored its
role in human breast cancer. In those, VEGF-C has been
proposed to be an inducer of tumor lymphangiogenesis
and, therefore, an important promoter of breast cancer
metastasis [7-9].
Angiogenesis is of central importance in the growth and
metastasis of tumors and in particular of breast cancer
[10,11]. Both VEGF-A and -B, and their receptors, have
been found to be expressed in several different tumor
types, including breast cancer [12]. Recently, VEGF-A has
emerged as an important factor for progression in many
tumor types and has been the target of bevacizumab [13].
However, its specific role in cancer has not been fully
elucidated as yet.
The prognostic and clinicopathological significance of
VEGF-A in breast cancer, both in node positive and node
negative patients [14,15], has been evaluated by ELISA
assays in several studies, less frequently and with contro-
versial results by immunohistochemistry [15] and even
less frequently by modern RT-PCR assays [16-18]. The
role of VEGF-B is even less studied and understood [19].
Tumor-induced lymphangiogenesis has only recently been
described and remains largely unexplored. Recent studies
have suggested that it is mainly driven by VEGF-A and
VEGF-C [20]. Furthermore, there is very limited informa-
tion regarding the predictive role of any of the VEGF
family members in breast cancer patients undergoing sys-
temic treatment, hormonal therapy and/or chemotherapy.
Although the expression of VEGF family members at
the protein level is well studied, the relationship of VEGF
family members mRNA expression with various para-
meters or tumor progression is unclear. Quantitative
RT-PCR (qRT-PCR) is a powerful tool that allows the
selective measurement of mRNA expression levels in
cancer cells, offering accurate relative quantification of
mRNA levels of specific biomarkers [21] in formalin-fixed
paraffin-embedded (FFPE) tumor tissue samples [22].
We initiated this study, with the aim of evaluating the
mRNA expression patterns of VEGF family members in
high-risk early breast cancer patients who had participated
in a large randomized adjuvant chemo-hormonotherapy
trial. We utilized a one-step qRT-PCR technique and cor-
related VEGF family members’ mRNA expression with
well-characterized clinicopathological parameters. Last but
not least, we sought to explore the prognostic/predictive
significance of mRNA expression of the evaluated VEGF
family members on disease-free survival (DFS) and overall
survival (OS) in high-risk operable breast cancer patients.
Materials and methods
Patient population
Tumor tissue samples were retrospectively obtained from
patients with high-risk operable breast cancer, who had
participated in a prospective randomized phase III study
of dose-dense sequential chemotherapy with epirubicin
(E), followed by intensified CMF with or without pacli-
taxel (T, Taxol®, Bristol Myers-Squibb, Princeton, NJ,
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USA), by the Hellenic Cooperative Oncology Group
(HE10/97). Due to the retrospective nature of the present
translational research study, collection of FFPE primary
tumor tissue samples was possible in 317 patients only,
due to logistical/organizational barriers. The clinical
study randomized a total of 595 high-risk (T1-3N1M0 or
T3N0M0) breast cancer patients from 1997 to 2000, in
order to explore the effect of dose-dense sequential che-
motherapy with or without paclitaxel (E-T-CMF versus
E-CMF), primarily on DFS and secondarily on OS. The
trial was included in the Australian New Zealand Clinical
Trials Registry (ANZCTR) and allocated Registration
Number ACTRN12611000506998. Chemotherapy cycles
were administered every two weeks and patients received
granulocyte-colony stimulating factor (G-CSF) support.
The present study was approved by the Bioethics Com-
mittee of the Aristotle University of Thessaloniki and
patients provided written informed consent prior to
enrollment. All participating patients also gave written
informed consent for research use of their biological
material. The results of the HE10/97 study have been
previously reported [23].
Data collected for this retrospective experimental
study included treatment arm, age, menopausal status,
interval from operation, number of positive nodes,
tumor size, histological grade and adjuvant radiotherapy/
hormonotherapy. Primary tumor diameter and axillary
nodal status were obtained from the pathology report.
Histological grade was evaluated according to the Scarff,
Bloom and Richardson system.
Tissue microarray construction
Representative H & E stained sections from the tissue
blocks were reviewed by a pathologist and the most repre-
sentative tumor areas were marked for the construction of
the tissue microarray (TMA) blocks, as previously
described [24]. Each case was represented by two tissue
cores, 1.5 mm in diameter, with each TMA block also
containing cores from various neoplastic, non-neoplastic
and reactive tissues serving as assay controls. Cases not
represented, damaged or inadequate on the TMA sections
were re-cut from the original blocks and these sections
were used for protein and gene analysis.
Immunohistochemistry
Immunohistochemistry (IHC) for ER (clone 6F11, Novo-
castra™, Leica Biosystems, Newcastle, UK), PgR (clone
1A6, Novocastra™, Leica Biosystems) and HER2 (A0485
polyclonal antibody, Dako, Glostrup, Denmark) was
performed on serial 2.5 μm thick TMA sections, using a
Bond Max™ autostainer (Leica Microsystems, Wetzlar,
Germany), as previously described [24]. All cases were also
stained for vimentin (clone V9, Dako) and cytokeratin 8/18
(clone 5D3, Novocastra™, Leica Biosystems), which were
used as control stains for tissue immunoreactivity and fixa-
tion, as well as identification of tumor cells. Tissue samples
negative for the above antibodies were excluded from the
study. The evaluation of all IHC sections was done by
experienced breast cancer pathologists, blinded as to the
patients’ clinical characteristics and survival data.
Interpretation of the immunohistochemistry results
ER, PgR and HER2 protein expression was evaluated
according to established or proposed criteria [25,26].
The ER and PgR immunostaining was scored using the
histoscore method. Tissue sections stained for ER/PgR
were considered to be positive when ≥1% of the neo-
plastic cells displayed nuclear immunoreactivity [25].
HER2 protein expression was scored according to the
recent guideline recommendations (scores 0 to 3+) [26].
HER2 was considered to be positive in cases with an
IHC score of 3+ (uniform, intense membrane staining in
>30% of the invasive tumor cells).
Fluorescence in situ hybridization
TMA sections or whole tissue sections (5 μm thick) were
used for fluorescence in situ hybridization (FISH) analysis,
using the ZytoLight® SPEC HER2/TOP2A/CEN17 triple
color probe (ZytoVision, Bremerhaven, Germany), as
previously described [27]. Four carcinoma cell lines
(MDA-MB-231, MDA-MB-175, MDA-MB-453, and SK-
BR-3) from the Oracle HER2 Control Slide (Leica Biosys-
tems), with a known HER2 gene status, were also used as
a control of the FISH assays and analyzed for HER2 geno-
mic status. TOP2A gene amplification was not evaluated
for the purposes of the present study.
For the evaluation of the HER2 gene status, non-
overlapping nuclei from the invasive part of the tumor
were randomly selected and scored. The virtual slides of
HER2, ER or PgR stains were used for selecting the inva-
sive part of the tumor in each TMA. The virtual slides
were created as previously described [28]. Twenty tumor
nuclei were counted according to Press et al. [29]. The
HER2 gene was considered to be amplified when the ratio
of the gene probe/centromere probe was ≥2.2 [26], or the
HER2 copy number was >6 [30]. In cases with values at or
near the cut-off (1.8 to 2.2), an additional 20 or 40 nuclei
were counted and the ratio was recalculated. In cases with
a borderline ratio at 60 nuclei, additional FISH assays were
performed in whole sections. HER2 was considered to be
positive if it was amplified (ratio ≥2.2 or copy number >6)
by FISH and/or a HER2 score of 3+ was obtained by IHC.
RNA isolation from formalin-fixed paraffin-embedded
tissue and quantitative reverse transcription-polymerase
chain reaction assessment
H & E sections from all available FFPE tissue specimens
were evaluated histologically by a certified pathologist
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who recorded percentage of tumor cell content in each
one. Prior to RNA isolation, macrodissection of tumor
areas was performed in most of the FFPE sections with
<50% tumor cell content. The tumor cell content was
>30% in practically all (97%) of the samples and >50% in
the majority (76%) of the samples. More than one FFPE
section was used for RNA extraction when the tumor
surface of a given sample was less than 0.25 cm2, in an
effort to minimize the rate of technical failures in the RNA
extraction.
Sufficient RNA was isolated from 308 FFPE specimens
followed by qRT-PCR, as previously described [31]. From
each FFPE section or macrodissected tissue fragment
(10 μm thick), RNA was isolated using a standardized fully
automated isolation method for total RNA from FFPE tis-
sue, based on silica-coated magnetic beads (VERSANT
Tissue Preparation Reagents, Siemens Healthcare Diag-
nostics, Tarrytown, NY, USA) in combination with a
liquid handling robot, as previously described in detail
[22]. The method involves extraction-integrated deparaffi-
nization and DNase I digestion steps. DNA-free total RNA
was eluted with 100 μL elution buffer and stored at -80°C.
One-step qRT-PCR was applied for the relative quantifi-
cation of VEGF-A, VEGF-B, VEGF-C, VEGFR1, VEGFR2
and VEGFR3 mRNA expression, by using gene-specific
TaqMan® based assays. Forty cycles of nucleic acid ampli-
fication were applied and the cycle threshold (CT) values
of the target genes were identified. CT values were nor-
malized by subtracting the CT value of the housekeeping
gene RPL37A (ribosomal protein L37a) from the CT value
of the target genes (ΔCT). RNA results were then reported
as 40-ΔCT values, which correlate proportionally with the
mRNA expression level of the target genes. For assessment
of DNA contamination, a qPCR analysis specific for the
PAEP gene (progestagen-associated endometrial protein)
was performed, without the preceding reverse-transcrip-
tion step. Samples were considered to be substantially free
of DNA when CT values above 38 were detected. In the
case of DNA contamination, samples were manually
re-digested with DNase I. The quantity of RNA following
isolation (yield) was checked by measuring RPL37A
expression as a surrogate marker for amplifiable mRNA.
Samples with average RPL37A CT values <32 were consid-
ered to have sufficient RNA and were eligible for analysis.
Only 3 of the 311 extracted samples (1%) had an average
RPL37A CT value of ≥32 and were, therefore, excluded
from further analysis, resulting in successful RNA extrac-
tion from 99% of the samples.
Expression of the target genes, as well as the reference
gene RPL37A, was assessed in triplicate by qRT-PCR using
the SuperScript III PLATINUM One-Step Quantitative
RT-PCR System with ROX (Invitrogen, Karlsruhe,
Germany) in an ABI PRISM 7900HT (Applied Biosystems,
Darmstadt, Germany) [21]. The lengths of the amplicons
detected by the VEGF-A, VEGF-B, VEGF-C, VEGFR1,
VEGFR2, VEGFR3 and RPL37A assays were 80 bp, 81 bp,
77 bp, 85 bp, 68 bp, 70 bp and 65 bp, respectively, with
PCR efficiencies [E = 1(10-slope)] of 85.5, 110.3, 88.2, 95.7,
94.3, 84.7 and 86.0%, respectively. A commercially avail-
able human reference RNA (Stratagene qPCR Human
Reference Total RNA, Agilent Technologies, Waldbronn,
Germany) was used as positive control. No-template con-
trols were assessed in parallel to exclude contamination.
The Primer/Probe (FAM/TAMRA-labeled) sets used
for amplification of the target and reference genes were
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Statistical analysis
For all VEGF family members the quartiles (first, median
and third) were examined as possible thresholds for prog-
nostic significance in terms of OS or DFS. If a cut-off
showed prognostic significance it was used to dichoto-
mize the tumors into low and high expressing tumors.
Otherwise, only the normalized mRNA expression values
were used in the analysis as a continuous variable to eval-
uate prognostic significance.
OS was measured from the date of randomization until
death from any cause. Surviving patients were censored
at the date of last contact. DFS was measured from the
date of randomization until recurrence of tumor, second-
ary neoplasm or death from any cause [32]. Time-to-
event distributions were estimated using Kaplan-Meier
curves. Continuous variables were presented as medians
with the corresponding range and categorical variables as
frequencies with the respective percentages. Associations
of ligands and receptors with basic patient and tumor
characteristics were examined using the Fisher’s exact
test for categorical variables and the Mann-Whitney or
the Kruskall-Wallis tests, where appropriate, for continu-
ous variables.
Correlations between the VEGF family ligands and
their associated receptors were calculated using the
Spearman’s rank correlation coefficient (Rho). Cox
regression analyses were performed to assess the rela-
tionship between markers and OS or DFS. Interactions
between markers and treatment group, as well as
between ligands and their associated receptors were also
explored in the Cox models. In the multivariate Cox
regression analysis, a backward selection procedure with
a removal criterion of P >0.10 based on the likelihood
ratio test was performed to identify significant variables
among the following: treatment group (E-CMF versus
E-T-CMF), menopausal status (post versus pre), time
interval from breast surgery operation (>4 weeks versus
2 to 4 weeks versus <2 weeks), histological grade (III-IV
versus I-II), tumor size (>5cm versus 2 to 5cm versus
≤2cm), number of positive axillary nodes (≥4 versus 0 to
3), ER/PgR status (positive versus negative versus miss-
ing), HER2 status (negative versus positive versus miss-
ing), hormonal therapy (yes versus no), radiotherapy
(yes versus no), VEGF-A (continuous mRNA values),
VEGF-B (continuous mRNA values), VEGF-C (high ver-
sus low at the 75th percentile), VEGFR1 (high versus
low at the 75th percentile), VEGFR2 (continuous mRNA
values), VEGFR3 (continuous mRNA values).
The design of the study is prospective-retrospective as
described in Simon et al. [33]. Results of this study are
presented according to reporting recommendations for
tumor marker prognostic studies [34]. The SPSS software
was used for statistical analysis (SPSS for Windows,
version 15.0, SPSS Inc.). No adjustment for multiple com-
parisons is reported.
Results
Patient and tumor characteristics
A total of 308 primary tumor tissue samples were ana-
lyzed as stated in the ‘Methods’ section. Basic clinical
and pathological characteristics of the patients (Table 1)
were well balanced according to adjuvant chemotherapy,
except for histological grade (P = 0.008), in agreement
with the corresponding results presented in the clinical
paper [23]. In addition, there were no significant differ-
ences in important clinicopathological characteristics
between the patients included in the present study and
the rest of the HE10/97 randomized patients, for which
tissue samples were not available.
The median follow-up period was eight years (range
7 to 126 months). A total of 109 patients developed a
relapse (35%) and 80 patients died (26%). Median OS has
not been reached yet, while median DFS was 121 months
(95% CI: 105 to 138). The five-year OS rate was 83%
(95% CI: 79 to 87) and the seven-year OS rate was 77%
(95% CI: 72 to 81). The five-year DFS rate was 71% (95%
CI: 66 to 76) and the seven-year DFS rate was 66% (95%
CI: 60 to 71).
Normalized mRNA expression
The distribution of normalized mRNA expression
(40-ΔCT values) of each VEGF family gene is shown in
Figure 1. The median value for VEGF-A was 35.0 (range:
28.2 to 38.3), for VEGF-B 35.5 (range: 27.5 to 38.0), for
VEGF-C 32.5 (range: 29.3 to 35.3), for VEGFR1 32.2
(range: 29.7 to 34.9), for VEGFR2 32.1 (range: 29.2
to 34.5) and for VEGFR3 32.0 (range: 27.4 to 34.4).
All examined genes followed a unimodal distribution
pattern.
Spearman’s correlations between ligands and their
associated receptors were examined. More specifically,
there were statistically significant weak to moderate
positive correlations between VEGF-A and receptors
VEGFR1 and 2, VEGF-B and VEGFR1, as well as
between VEGF-C and receptors VEGFR2 and 3 (Rho
ranges from 0.30 to 0.56, P <0.001 in all cases), in agree-
ment with the expected binding of the ligands.
Associations of vascular endothelial growth factor family
gene expression with patient and tumor characteristics
The mRNA expression of all VEGF family genes was
evaluated for associations with the following patient and
tumor characteristics: age, treatment group, menopausal
status, ER/PgR status, HER2 status, number of positive
nodes, tumor size, histological grade and adjuvant treat-
ment (hormonal and radiation therapy).
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Table 1 Basic patient and tumor characteristics.
E-T-CMF E-CMF All patients
Number 141 167 308
Age (years)
Median 50 50 50
Range 24 to 76 22 to 78 22 to 78
Number of nodes removed
Median 19 20 20
Range 5 to 59 4 to 53 4 to 59
Number of positive nodes
Median 7 6 6
Range 0 to 54 0 to 49 0 to 54
N % N % N %
0 to 3 nodes 30 21.3 45 26.9 75 24.4
≥4 111 78.7 122 73.1 233 75.6
Menopausal status
Premenopausal 76 53.9 89 53.3 165 53.6
Postmenopausal 65 46.1 78 46.7 143 46.4
Type of operation
Modified radical mastectomy 111 78.7 132 79.0 243 78.9
Breast conserving surgery 30 21.3 35 21.0 65 21.1
Interval from operation
<2 weeks 17 12.1 24 14.4 41 13.3
2 to 4 weeks 72 51.1 70 41.9 142 46.1
>4 weeks 52 36.9 73 43.7 125 40.6
Tumor size
≤2cm 40 28.4 52 31.1 92 29.9
2 to 5cm 79 56.0 83 49.7 162 52.6
>5cm 22 15.6 32 19.2 54 17.5
Histological gradea
I-II 60 42.6 97 58.1 157 51.0
III-IV 81 57.4 70 41.9 151 49.0
ER/PgR status
Negative 28 19.9 29 17.4 57 18.5
Positive 95 67.4 108 64.7 203 65.9
Missing data 18 12.8 30 18.0 48 15.6
HER2 statusb
Negative 79 56.0 100 59.9 179 58.1
Positive 35 24.8 32 19.2 67 21.8
Missing data 27 19.1 35 21.0 62 20.1
Adjuvant RT
No 21 14.9 33 19.8 54 17.5
Yes 119 84.4 133 79.6 252 81.8
Missing data 1 0.7 1 0.6 2 0.6
Adjuvant HT
No 8 5.7 18 10.8 26 8.4
Yes 133 94.3 149 89.2 282 91.6
Tamoxifen 120 85.1 127 76.0 247 80.2
LH-RH agonist 65 46.1 62 37.1 127 41.2
Aromatase inhibitors 5 3.5 6 3.6 11 3.6
Other 1 0.7 2 1.2 3 1.0
aThe two treatment arms were not balanced in terms of histological grade (P = 0.008); bpositive HER2 status: HER2 3+ by IHC and/or HER2 amplification by FISH.
CMF, cyclophosphamide, methotrexate, fluorouracil; ER, estrogen receptor; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor
2; HT, hormonal therapy; IHC, immunohistochemistry; LH-RH, luteinizing hormone-releasing hormone; PgR, progesterone receptor; RT, radiation therapy.
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Concerning VEGF-A, higher continuous mRNA expres-
sion values were associated with higher age (≥50 years,
Mann-Whitney test, P = 0.001), postmenopausal status
(P = 0.001), negative ER/PgR status (P <0.001), positive
HER2 status (P = 0.020), higher grade (III-IV, P = 0.027)
and no adjuvant hormonal therapy (P = 0.003). Higher
VEGF-B mRNA expression values were associated with
higher age (P <0.001), postmenopausal status (P = 0.002),
positive ER/PgR status (P = 0.023) and lower grade (I-II,
P = 0.024). No statistically significant associations were
found for VEGFR2, while higher mRNA expression values
of VEGFR3 were associated with higher age (P = 0.030)
(Table 2).
Associations of VEGF-C and VEGFR1 mRNA status
(high versus low at the 75th percentile) with selected clin-
icopathological factors are shown in Table 3. High
mRNA expression of VEGF-C was associated with higher
age (≥50 years, Fisher’s exact test, P = 0.024), while
ER/PgR-negative tumors were more frequent in high
VEGF-C expressing tumors (37.7% in high versus 17.3%
in low, P = 0.001). Similarly, HER2-positive tumors were
more frequent in high VEGF-C expressing tumors (46.6%
in high versus 21.5% in low, P <0.001). Overall, high
VEGF-C expression was more frequent in ER/PgR-negative
and HER2-positive tumors. The number of positive lymph
nodes did not seem to be associated with the expression of
VEGF-C (P = 0.17). Concerning VEGFR1, ER/PgR-negative
tumors and HER2-positive tumors were more frequent in
high VEGFR1 expressing tumors (33.3% in high versus
18.8% in low, P = 0.021 and 39.7% in high versus 23.7% in
low, P = 0.028, respectively). Finally, high expression of
VEGFR1 was associated with adjuvant radiotherapy (P =
0.036).
Association of vascular endothelial growth factor ligands
with survival
VEGF-A and VEGF-B
VEGF-A and VEGF-B mRNA values did not achieve prog-
nostic significance in any of the distribution cut-offs exam-
ined. Cox regression analysis, adjusted for treatment
group, for the continuous normalized mRNA expression
values of VEGF-A failed to establish a distinct risk for
death (HR = 1.14, 95% CI: 0.94 to 1.39, Wald’s P = 0.18)
or risk for relapse (HR = 1.09, 95% CI: 0.92 to 1.29, P =
0.30). Similarly, normalized mRNA expression values of
VEGF-B did not have prognostic significance for OS
Figure 1 Distribution of mRNA expression values. Normalized mRNA expression values (40-delta CT) of all qRT-PCR evaluated VEGF family
members are presented. CT, cycle threshold; VEGF, vascular endothelial growth factor.
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(HR = 0.86, 95% CI: 0.71 to 1.05, Wald’s P = 0.14) or DFS
(HR = 0.93, 95% CI: 0.77 to 1.14, P = 0.50) when analyzed
as a continuous variable.
Patients were randomized to a taxane-free versus a tax-
ane-containing chemotherapy and, thus, the predictive sig-
nificance of VEGF markers for the paclitaxel-containing











































































































































































































Normalized mRNA expression values (40-delta CT) are presented. Comparisons were made using the Mann-Whitney test, except for tumor size where the
Kruskall-Wallis test was used. aPositive HER2 status: HER2 3+ by IHC and/or HER2 amplification by FISH. Significant P values are shown in bold. CMF,
cyclophosphamide, methotrexate, fluorouracil; CT, cycle threshold; ER, estrogen receptor; FISH, fluorescence in situ hybridization; HER2, human epidermal growth
factor receptor 2; HT, hormonal therapy; PgR, progesterone receptor; RT, radiation therapy; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial
growth factor receptor.
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adjuvant chemotherapy treatment was examined as well.
There was no significant interaction between VEGF-A and
VEGF-B with chemotherapy treatment in terms of OS or
DFS (tests for interaction, Wald’s P >0.062 in all cases).
VEGF-C
The cut-off for VEGF-C was set at the 75th percentile of
the marker’s distribution. VEGF-C was predictive for
benefit from adjuvant treatment with paclitaxel (E-T-
CMF arm) for OS (test for interaction, Wald’s P = 0.038),
and marginally significant for DFS (test for interaction,
Wald’s P = 0.055). The impact of VEGF-C expression on
OS and DFS in the two treatment groups is shown in
Figure 2. Patients with high VEGF-C mRNA expression
randomized to the non paclitaxel-containing adjuvant
chemotherapy arm (E-CMF) had decreased OS and DFS
(log-rank, P = 0.001 and P = 0.005, respectively; HR for
OS = 2.57, 95% CI: 1.42 to 4.65; HR for DFS = 2.10, 95%
CI: 1.26 to 3.51) compared to the patients with low
VEGF-C expression, while no difference in OS or DFS
was detected in the E-T-CMF group (log-rank, P = 0.72
and P = 0.67, respectively; HR for OS = 0.84, 95% CI:
0.35 to 2.02 for high VEGF-C expression; HR for DFS =
0.89, 95% CI: 0.44 to 1.80 for high VEGF-C expression).
Association of vascular endothelial growth factor
receptors with survival
For the VEGFR1 receptor the 75th percentile was prog-
nostic for both OS and DFS, while for the VEGFR2 and
VEGFR3 receptors no prognostic significance was found
in the examined cut-offs in terms of OS or DFS. Con-
cerning VEGFR1, 27/76 deaths (36%) and 37/76 relapses
(49%) occurred in patients with high expressing tumors,
in comparison to 52/230 deaths (23%) and 76/230
relapses (33%) in the low expressing tumors. Moreover,
patients with high mRNA expression of VEGFR1 had
increased risk for death (HR = 1.60, 95% CI: 1.01 to 2.55,
Wald’s P = 0.047) and increased risk for relapse (HR =
1.67, 95% CI: 1.13 to 2.48, P = 0.010) compared to
patients with low expressing tumors when adjusting for
treatment group. Kaplan-Meier curves for OS and DFS
according to the mRNA status of VEGFR1 are presented
in Figure 3.





Low (n = 229)
Number (%)
High (n = 76)
Number (%)
P value Low (n = 230)
Number (%)
High (n = 76)
Number (%)
P value
Age <50 123 (53.9) 29 (38.2) 0.024 118 (51.5) 35 (46.1) 0.43
≥50 105 (46.1) 47 (61.8) 111 (48.5) 41 (53.9)
Treatment group E-T-CMF 113 (49.3) 28 (36.8) 0.064 110 (47.8) 30 (39.5) 0.23
E-CMF 116 (50.7) 48 (63.2) 120 (52.2) 46 (60.5)
Menopausal status Premenopausal 130 (56.8) 34 (44.7) 0.084 128 (55.7) 37 (48.7) 0.35
Postmenopausal 99 (43.2) 42 (55.3) 102 (44.3) 39 (51.3)
ER/PgR status Negative 34 (17.3) 23 (37.7) 0.001 37 (18.8) 20 (33.3) 0.021
Positive 162 (82.7) 38 (62.3) 160 (81.2) 40 (66.7)
HER2 Statusa Negative 146 (78.5) 31 (53.5) <0.001 142 (76.3) 35 (60.3) 0.028
Positive 40 (21.5) 27 (46.6) 44 (23.7) 23 (39.7)
Positive nodes 0-3 61 (26.6) 14 (18.4) 0.17 61 (26.5) 14 (18.4) 0.17
≥4 168 (73.4) 62 (81.6) 169 (73.5) 62 (81.6)
Tumor size ≤2 61 (26.6) 30 (39.5) 0.093 64 (27.8) 27 (35.5) 0.40
2-5 127 (55.5) 33 (43.4) 123 (53.5) 38 (50.0)
>5 41 (17.9) 13 (17.1) 43 (18.7) 11 (14.5)
Histological grade I-II 113 (49.3) 41 (53.9) 0.51 118 (51.3) 37 (48.7) 0.79
III-IV 116 (50.7) 35 (46.1) 112 (48.7) 39 (51.3)
Adjuvant HT No 17 (7.4) 9 (11.8) 0.24 20 (8.7) 6 (7.9) 0.99
Yes 212 (92.6) 67 (88.2) 210 (91.3) 70 (92.1)
Adjuvant RT No 43 (18.9) 11 (14.5) 0.49 47 (20.5) 7 (9.3) 0.036
Yes 184 (81.1) 65 (85.5) 182 (79.5) 68 (90.7)
Cut-off values were set at the 75th percentile of the marker’s distribution. Comparisons were made using the Fisher’s exact test. aPositive HER2 status: HER2 3+
by IHC and/or HER2 amplification by FISH. Significant P values are shown in bold. CMF, cyclophosphamide, methotrexate, fluorouracil; ER, estrogen receptor; FISH,
fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; HT, hormonal therapy; PgR, progesterone receptor; RT, radiation therapy;
VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
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Examining continuous normalized mRNA expression
values of VEGFR2, Cox regression analysis, adjusted for
treatment group, did not show any associations with OS
(HR = 1.10, 95% CI: 0.88 to 1.38, Wald’s P = 0.41), or
DFS (HR = 1.12, 95% CI: 0.93 to 1.35, P = 0.23). Similarly,
normalized mRNA values of VEGFR3 did not have prog-
nostic significance for OS (HR = 0.97, 95% CI: 0.78
to 1.19, Wald’s P = 0.75), or DFS (HR = 1.07, 95% CI:
0.89 to 1.28, P = 0.47) when analyzed as a continuous
variable.
Regarding predictive ability, there were no significant
interactions between VEGF receptors and adjuvant
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Figure 2 Kaplan-Meier curves according to VEGF-C mRNA expression and treatment. OS and DFS for patients with low VEGF-C mRNA
expression (blue line) and high VEGF-C mRNA expression (red line) randomized in the E-T-CMF and E-CMF treatment groups. Interaction
between VEGF-C mRNA expression and treatment group was significant for OS (P = 0.019) and DFS (P = 0.041). CMF, cyclophosphamide,
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Figure 3 Kaplan-Meier curves according to VEGFR1 mRNA expression. High mRNA expression of VEGFR1 (above the 75th percentile) was
associated with significantly reduced OS (left) and DFS (right). DFS, disease-free survival; OS, overall survival; VEGFR1, vascular endothelial growth
factor receptor 1.
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Interactions between ligands and receptors
Interactions between all possible combinations of ligands
and receptors (VEGF-A*VEGFR1, VEGF-A*VEGFR2,
VEGF-B*VEGFR1, VEGF-C*VEGFR2, VEGF-C*VEGFR3)
were tested, both for OS and DFS. The interaction
between VEGF-A and VEGFR1, adjusted for treatment
group, was found to be significant in terms of OS (Wald’s
P = 0.017). More specifically, for those patients with low
expression of VEGFR1 a one unit rise of the VEGF-A
mRNA expression value would lead to increased risk for
death with an HR of 1.43 (95% CI: 1.11 to 1.83), whereas
for patients with high expression of VEGFR1 a one unit
rise of the VEGF-A mRNA expression value would lead to
an HR for OS of 0.84 (95% CI: 0.59 to 1.20).
Multivariate Cox regression model for overall survival and
disease-free survival adjusting for clinical parameters
The Cox multivariate regression analysis for OS (Table 4)
revealed that the hazard of death at any time was signifi-
cantly higher for patients with more than three positive
nodes (HR = 2.58, 95% CI: 1.32 to 5.02, Wald’s P =
0.005), higher histological grade (HR = 1.94, 95% CI: 1.21
to 3.11, P = 0.006) and no hormonal therapy (HR = 2.86,
95% CI: 1.56 to 5.26, P = 0.001). Among the VEGF family
members evaluated, VEGF-B and VEGF-C were asso-
ciated with risk for death. For a one-unit increase in the
mRNA expression of VEGF-B there was an 18% decrease
in risk for death (P = 0.019). There was also a statistically
significant difference in the treatment effect according to
VEGF-C expression (P for interaction 0.019). The same
clinicopathological factors had significant prognostic
value for DFS: high histological grade (III-IV, P = 0.002),
four or more positive nodes (P <0.001) and adjuvant hor-
monal therapy (P = 0.008), while VEGF-B (P = 0.084),
VEGFR1 (P = 0.060) and the change in treatment effect
on the hazard for disease progression according to
VEGF-C mRNA expression were also statistically signifi-
cant (P for interaction 0.041). Overall, there was a
decreased, but not significant, risk for death in tumors
with high VEGF-C expression (HR = 0.74, 95% CI: 0.28
to 1.96, P = 0.547), as well as a non-significant decreased
risk for relapse (HR = 0.68, 95% CI: 0.31 to 1.48, P =
0.327) in the E-T-CMF group. Regarding the E-CMF
group, high expression of VEGF-C increased the risk for
death (HR = 2.85, 95% CI: 1.55 to 5.22, Wald’s P <0.001)
and the risk for relapse (HR = 1.73, 95% CI: 0.98 to 3.08,
P = 0.166).
Discussion
Experimental and clinical evidence is rapidly accumulat-
ing regarding the significant role of angiogenesis in
breast cancer progression and metastasis. VEGF has
emerged as possibly the most essential angiogenic factor,
expressed in many tumors including breast cancer,
where it has been investigated for more than a decade
now for its prognostic significance [35]. In most studies,
VEGF expression is measured by IHC [36] or ELISA
[37], but recently, PCR-based methods have also been
used to assess VEGF mRNA expression in tumor tissues
[38]. In general, PCR-based methods have proven to be
very effective for the quantitative analysis of gene copy
number or mRNA, especially when only a limited
amount of tissue is available [39,40], while recent publi-
cations have shown that total RNA isolated from FFPE
tissue samples can be used for reliable gene expression
analysis [22,41]. Furthermore, Oncotype DX is a clini-
cally validated prognostic test for patients with breast
cancer, based on a qRT-PCR multigene algorithm [42].
Table 4 Multivariate analysis for prognostic significance:
parameters in the final Cox model.
Overall survival HR 95% CI Wald’s P
Histological grade
III-IV versus I-II 1.94 1.21-3.11 0.006
Number of positive nodes
≥4 versus 0 to 3 2.58 1.32-5.02 0.005
Adjuvant HT
No versus Yes 2.86 1.56-5.26 0.001
VEGF-B
Continuous mRNA values 0.82 0.69-0.97 0.019
VEGF-C/Treatment group Interaction 3.84 1.24-11.84 0.019
Treatment group
E-CMF versus E-T-CMF for VEGF-C low 0.96 0.54-1.70 0.885
E-CMF versus E-T-CMF for VEGF-C high 3.68 1.38-9.80 0.009
VEGF-C
High versus Low for E-T-CMF 0.74 0.28-1.96 0.547
High versus Low for E-CMF 2.85 1.55-5.22 <0.001
Disease-free survival HR 95% CI Wald’s P
Histological grade
III-IV versus I-II 1.83 1.24-2.71 0.002
Number of positive nodes
≥4 versus 0 to 3 2.80 1.58-4.95 <0.001
Adjuvant HT
No versus Yes 2.16 1.22-3.84 0.008
VEGF-B
Continuous mRNA values 0.86 0.72-1.02 0.084
VEGFR1
High versus Low 1.58 0.98-2.55 0.060
VEGF-C/Treatment group Interaction 2.56 1.04-6.31 0.041
Treatment group
E-CMF versus E-T-CMF for VEGF-C low 0.95 0.60-1.52 0.846
E-CMF versus E-T-CMF for VEGF-C high 2.44 1.12-5.31 0.057
VEGF-C
High versus Low for E-T-CMF 0.68 0.31-1.48 0.327
High versus Low for E-CMF 1.73 0.98-3.08 0.166
CI, confidence interval; CMF, cyclophosphamide, methotrexate, fluorouracil;
HR, hazard ratio; HT, hormonal therapy; VEGF, vascular endothelial growth
factor.
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It is worth noting that Oncotype DX does not include
angiogenesis markers, but rather proliferation genes and
other known prognostic genes, such as ER and HER2;
therefore, the identification of useful prognostic indicators
among the VEGF family members could have potential
applications in similar multigene platforms. Furthermore,
evidence is lacking on the ability of VEGF family members
to predict benefit from specific treatments, especially on
their predictive value for bevacizumab use. Several inter-
esting candidate biomarkers for anti-angiogenic therapies
have been evaluated in recent translational research stu-
dies and many are currently under investigation in pro-
spective clinical trials. A recent report has shed some light
on this issue by exploring biomarkers of the VEGF family
for their possible effect on bevacizumab [43]. Results were
only indicative that patients with low VEGF-C, among
other markers, show trends toward improvement in pro-
gression-free survival associated with the addition of beva-
cizumab to capecitabine. Also, in a recently published
biomarker evaluation study from the AVAGAST rando-
mized trial in advanced gastric cancer, plasma VEGF-A
and neuropilin-1 emerged as potential predictors of beva-
cizumab response [44].
In the present study, we analyzed the mRNA expres-
sion of well-recognized VEGF family members, including
receptors (VEGFR1, 2 and 3) and their ligands (VEGF-A,
B and C) in an attempt to identify individual members
with prognostic/predictive significance. Our patient
cohort included early breast cancer patients with high-
risk characteristics: half were premenopausal, the major-
ity had ≥4 positive axillary lymph nodes, large tumor size
in most cases, almost half had high grade tumors, while
18.5% had ER/PgR-negative and 21.8% HER2-positive
tumors. These patients participated in an adjuvant clini-
cal study and were randomized to receive anthracycline-
based chemotherapy with or without a taxane (E-T-CMF
versus E-CMF). In this high-risk population, increased
levels of VEGF-A mRNA were significantly associated
with certain negative prognostic indicators, such as nega-
tive ER/PgR status, higher histological grade, positive
HER2 status and no adjuvant hormonal therapy. VEGF-A
mRNA levels have previously been associated with breast
tumor characteristics, such as histological type and grade,
albeit with variable results [45,46].
The prognostic value of VEGF family members on
survival has been assessed in our patient population.
Neither VEGF-A nor -B had prognostic significance for
OS; they had no significant interaction with the che-
motherapy treatment arm. With regard to receptors,
only high expression of VEGFR1 was prognostic for
both OS and DFS.
The prognostic value of VEGF-A expression has been
assessed by IHC in several studies [15,19,37]. Recent retro-
spective clinical studies have strengthened the prognostic
significance of total VEGF, as assessed by IHC in breast
cancer [47,48], and have resulted in the recognition of the
importance of VEGF as a possibly predictive biomarker
and target for therapy in the more aggressive subcategory
of triple-negative breast cancer [49,50]. Recent clinical evi-
dence also strengthens the need for anti-angiogenic treat-
ment in the triple-negative subtype, as bevacizumab added
to neoadjuvant chemotherapy significantly increased the
pathological complete response among patients with HER-
negative early breast cancer, and primarily, those with
triple-negative tumors [51]. However, in all of the above-
mentioned studies, VEGF expression was assessed with
standard IHC methods only [15,19,37,47-51]. In our study
population, total VEGF had previously been assessed by
IHC together with HER2, and, while HER2 was a negative
prognostic indicator, high VEGF protein expression was
not significantly associated with either DFS or OS [52].
It is important to note that, in our patient cohort, high
mRNA expression of VEGFR1 had prognostic signifi-
cance and, furthermore, the interaction of VEGF-A with
VEGFR1 showed prognostic significance as well, while
high expression of the ligand alone did not. This under-
lines the possible importance of interactions within the
VEGF family, rather than that of individual members,
and strengthens the need for further investigation. The
binding of multiple ligands to individual receptors has
previously been described [39]; however, certain interac-
tions appear to be more important than others. Accord-
ing to the findings of our study, the correlation of VEGF-
A with tumor profile, namely that higher expression was
to be expected when the tumor was more aggressive, is
not reflected by a negative prognostic effect on OS or
DFS. There is, however, evidence of a negative prognostic
role of increased VEGF-A mRNA expression in the low
VEGFR1 subgroup with respect to OS. This particular
subgroup of patients has a more favorable tumor profile
in terms of ER/PgR and HER2 than the subgroup with
high VEGFR1 levels. Therefore, a larger study should be
conducted to explore whether the strong effect on DFS/
OS exhibited by the receptor (VEGFR1) is masking the
possible prognostic value of the VEGF-A ligand.
The most significant findings in our study involved
VEGF-C; this factor emerged as a very important mem-
ber of the VEGF family. In agreement with recent evi-
dence from a number of studies, associations were found
with VEGF-C and aggressive phenotype characteristics;
ER/PgR-negative tumors and HER2-positive tumors had
high VEGF-C expression more frequently. It is known
that VEGF-C is a potent enhancer of tumor lymphangio-
genesis, leading to increased metastatic spread of breast
cancer cells to lymph nodes; however, in our study no
significant correlation was found between the level of
VEGF-C mRNA expression (low/high) and the number
of positive lymph nodes (0 to 3 versus ≥4). However, it
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needs to be noted that the vast majority of patients in our
study had large numbers of positive lymph nodes (>75%
of the patients had ≥4 positive axillary lymph nodes);
therefore, conclusive correlations were not possible. In a
previous study, a significant association between
increased VEGF-C expression and advanced histological
grade was found, suggesting that poorly differentiated
tumor cells may be more capable of secreting VEGF-C,
which can induce lymphangiogenesis in breast cancer
[47], while VEGF-C together with extracellular matrix
protein 1 were found overexpressed in breast cancer lym-
phatic metastases [53]. It is also important to note that in
our study, high VEGF-C and VEGFR1 mRNA expression
was more frequently seen in HER2-positive tumors, indi-
cating that certain VEGF family members could prove to
be even more useful when analyzed in combination with
other markers, with potential, for instance, to recognize
patients with poor prognosis among the HER2-positive
or, more importantly, the HER2-negative populations.
An important finding in our study was the predictive
significance of VEGF-C and the impact of the taxane-
containing treatment arm. Patients with high VEGF-C
expressing tumors benefited more from the addition of
paclitaxel in terms of OS. This was also evident in the
multivariate analysis: patients with high VEGF-C mRNA
expression were those with the worse prognosis, and they
appear to benefit more from the taxane-containing treat-
ment, possibly through the potential anti-angiogenic
properties of the taxane therapy. Weekly taxane adminis-
tration is considered very effective, both in the neoadju-
vant and metastatic settings [54,55] and recently in the
adjuvant setting [56]. Furthermore, there is evidence for
anti-angiogenic effects of this schedule in addition to the
anti-microtubule properties [57]. In our study, taxane
treatment was indeed delivered in a dose-dense manner,
every two weeks. The interaction of VEGF-C expression
with treatment provides a significant indication for a pos-
sible predictive role of mRNA expression of VEGF family
members, a role that warrants further evaluation in larger
studies.
In our study, VEGF family mRNA expression and, in
particular, high VEGF-C and VEGFR1 expression, was
able to identify those patients with early breast cancer
who have a higher likelihood of recurrence or death than
those with low-angiogenic tumors, even if treated with
adjuvant chemo-hormonotherapy. The taxane-containing
treatment administered in a dose-dense manner, might
have offered anti-angiogenic effects, which seem to be of
more benefit for those patients with a high expression of
angiogenic markers, such as VEGF-C and VEGFR1. The
high expression of these factors might reflect subcate-
gories of high-angiogenic tumors. It may be that such
patient subsets represent good candidates for testing
additional strategies to complement chemotherapy, such
as anti-VEGF targeting agents in combination with con-
ventional therapies. The results of our study provide the
first evidence toward the identification of relevant angio-
genic biomarkers in dose-dense chemotherapy regimens.
Recent evidence of the strong predictive value of VEGF
in premenopausal early breast cancer patients [58], as
well as the predictive significance of tumor angiogenesis
in high-risk early breast cancer patients [59], underlines
the need for additional studies that could possibly sup-
port and/or clarify these findings.
Conclusions
In conclusion, the present study reports, for the first
time, that VEGF-C mRNA overexpression, as assessed by
qRT-PCR, has a strong predictive value in high-risk early
breast cancer patients undergoing adjuvant dose-dense
taxane-containing chemotherapy. Further studies are
warranted to validate the prognostic and/or predictive
value of VEGF-B, VEGF-C and VEGFR1 in patients trea-
ted with adjuvant therapies and to reveal which members
of the VEGF family might possibly be useful in identify-
ing those patients who will benefit most from anti-VEGF
strategies.
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